Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer: A preliminary report

Thrombosis and Haemostasis

Volumn 102, Issue 4, 2009, Pages 765-771

  Levy, Jerrold H ^a   Gill, Ravi ^b   Nussmeier, Nancy A ^c   Olsen, Peter Skov ^d   Andersen, Henning F ^e   Booth, Frank V McL ^f   Jespersen, Christian M ^e  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Southampton   (United Kingdom)

^c State University of New York Upstate Medical University: College of Medicine   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e NOVO NORDISK A S   (Denmark)

^f NOVO NORDISK INC   (United States)

Author keywords

Cardiac surgery; FXIII; Pharmacokinetics; Safety

Indexed keywords

BERICHROM; BLOOD CLOTTING FACTOR 13; HEART ENZYME; HOMODIMER; PLACEBO; PROTAMINE; RECOMBINANT BLOOD CLOTTING FACTOR 13 A2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; MALE; MORBIDITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; SINGLE DRUG DOSE;

ADULT; AGED; ANTICOAGULANTS; BLOOD COAGULATION; CARDIOPULMONARY BYPASS; FACTOR XIII; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROTEIN MULTIMERIZATION; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 70449491122     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-12-0826     Document Type: Article

References (17)

1. Karkouti K, O'Farrell R, Yau TM, et al; Reducing Bleeding in Cardiac Surgery Research Group. Prediction of massive blood transfusion in cardiac surgery. Can J Anaesth 2006; 53: 781-794.
2. Paparella D, Brister SJ, Buchanan MR. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med 2004; 30: 1873-1881. (Pubitemid 39468407)
3. Despotis GJ, Goodnough LT. Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery. Ann Thorac Surg 2000; 70 (2 Suppl): S20-S32.
4. Hein OV, Birnbaum J, Wernecke KD, et al. Threeyear survival after four major post-cardiac operative complications. Crit Care Med 2006; 34: 2729-2737. (Pubitemid 44610937)
5. Gödje O, Gallmeier U, Schelian M, et al. Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thorac Cardiovasc Surg 2006; 54: 26-33. (Pubitemid 43232140)
6. Gödje O, Haushofer M, Lamm P, et al. The effect of factor XIII on bleeding in coronary surgery. Thorac Cardiovasc Surg 1998; 46: 263-267. (Pubitemid 28562035)
7. Chandler WL, Patel MA, Gravelle L, et al. Factor XIIIA and clot strength after cardiopulmonary bypass. Blood Coagul Fibrinolysis 2001; 12: 101-108. (Pubitemid 32234817)
8. Bishop PD, Teller DC, Smith RA, et al. Expression, purification, and characterization of human factor XIII in Saccharomyces cerevisiae. Biochemistry 1990; 29: 1861-1869.
9. Cohn LH, Edmunds LH. Cardiac surgery in the adults, 2nd ed. New York: McGraw-Hill; 2003.
10. Weiler JM, Gellhaus MA, Carter JG, et al. A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery. J Allergy Clin Immunol 1990; 85: 713-719.
11. Wang S, Tang H, Wilkinson V, et al. Saphenous vein harvest with SaphLITE system versus conventional technique: a prospective, randomized study. Ann Thorac Surg 2005; 79: 2018-2023. (Pubitemid 40804180)
12. Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res 1999; 94: 271-305. (Pubitemid 29268348)
13. Ofosu FA, Freedman J, Semple JW: Plasma-derived biological medicines used to promote haemostasis. Thromb Haemost 2008; 99: 851-862. (Pubitemid 351705301)
14. Pipe SW: Recombinant clotting factors. Thromb Haemost 2008; 99: 840-850.
15. Lahav J, Karniel E, Bagoly Z, et al. Coagulation factor XIII serves as protein disulfide isomerase. Thromb Haemost 2009; 101: 840-844
16. de la Red G, Tassies D, Espinosa G, et al. Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels. Thromb Haemost 2009; 101: 312-316
17. Rallidis LS, Politou M, Komporozos C, et al. Factor XIII Val34Leu polymorphism and the risk of myocardial infarction under the age of 36 years. Thromb Haemost 2008; 99: 1085-1089 (Pubitemid 351810491)